Beacon Investment Advisory Services Inc. lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 0.4% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 217,027 shares of the company’s stock after purchasing an additional 903 shares during the quarter. Johnson & Johnson comprises 1.7% of Beacon Investment Advisory Services Inc.’s holdings, making the stock its 15th biggest position. Beacon Investment Advisory Services Inc.’s holdings in Johnson & Johnson were worth $30,521,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Sofos Investments Inc. lifted its stake in Johnson & Johnson by 172.0% in the 1st quarter. Sofos Investments Inc. now owns 1,148 shares of the company’s stock valued at $33,000 after acquiring an additional 726 shares in the last quarter. Altshuler Shaham Ltd acquired a new stake in Johnson & Johnson in the first quarter valued at approximately $35,000. Lake Point Wealth Management lifted its holdings in shares of Johnson & Johnson by 144.4% in the first quarter. Lake Point Wealth Management now owns 286 shares of the company’s stock valued at $38,000 after purchasing an additional 169 shares in the last quarter. Lion Street Advisors LLC bought a new position in shares of Johnson & Johnson in the first quarter valued at approximately $45,000. Finally, SeaBridge Investment Advisors LLC lifted its holdings in Johnson & Johnson by 160.0% during the second quarter. SeaBridge Investment Advisors LLC now owns 325 shares of the company’s stock worth $46,000 after acquiring an additional 200 shares during the period. Hedge funds and other institutional investors own 68.44% of the company’s stock.
In other Johnson & Johnson news, EVP Ashley Mcevoy sold 29,000 shares of the company’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $147.47, for a total value of $4,276,630.00. Following the completion of the transaction, the executive vice president now owns 21,682 shares in the company, valued at $3,197,444.54. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.27% of the company’s stock.
Several analysts have issued reports on the company. Citigroup boosted their target price on Johnson & Johnson from $165.00 to $170.00 and gave the company a “buy” rating in a research note on Friday, July 17th. UBS Group cut Johnson & Johnson from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $163.00 to $160.00 in a research report on Tuesday, April 28th. Stifel Nicolaus boosted their target price on Johnson & Johnson from $140.00 to $155.00 and gave the stock a “hold” rating in a research report on Wednesday, April 15th. Barclays upped their price objective on Johnson & Johnson from $173.00 to $182.00 and gave the stock an “overweight” rating in a report on Wednesday, April 29th. Finally, Raymond James boosted their target price on Johnson & Johnson from $157.00 to $158.00 and gave the company an “outperform” rating in a research note on Friday, July 17th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and twelve have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $163.38.
Johnson & Johnson stock opened at $145.76 on Friday. The company has a market capitalization of $383.76 billion, a PE ratio of 21.31, a P/E/G ratio of 3.23 and a beta of 0.69. Johnson & Johnson has a fifty-two week low of $109.16 and a fifty-two week high of $157.00. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.05 and a current ratio of 1.25. The company has a 50 day moving average price of $144.04 and a 200-day moving average price of $144.14.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Thursday, July 16th. The company reported $1.67 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.50 by $0.17. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.21%. The business had revenue of $18.34 billion for the quarter, compared to analyst estimates of $17.73 billion. During the same period in the previous year, the company earned $2.58 earnings per share. The business’s revenue for the quarter was down 10.8% on a year-over-year basis. On average, analysts forecast that Johnson & Johnson will post 7.85 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be given a $1.01 dividend. The ex-dividend date is Monday, August 24th. This represents a $4.04 dividend on an annualized basis and a dividend yield of 2.77%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 46.54%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Read More: What is a Derivative?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.